Proposed Biosite-Beckman Merger Clears Antitrust Hurdle
Biosite said this week that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 had expired without a request from the US Federal Trade Commission for additional information about Biosite’s proposed merger with Beckman Coulter, removing one hurdle from the $1.55 billion deal to proceed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
